Clinical Trial Update: A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation [Phase 3]

View source ↗

Summary

A Phase 3 rollover safety study evaluating lumacaftor/ivacaftor in cystic fibrosis patients aged 2 years and older with the F508del-CFTR mutation has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Lumacaftor/Ivacaftor

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2020-08-07